A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies.
Chemotherapy with VP16-213 and cisplatin was administered to three patients with ovarian germ cell malignancies resistant to chemotherapy with methotrexate, actinomycin D, and chlorambucil and with vinblastine, bleomycin, and cisplatin. Remission was achieved in all patients and has been sustained for 9 to 50 months. Use of these agents in a salvage regimen for resistant germ cell malignancies is recommended.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004407:Dysgerminoma / Q000188:drug therapy* / Q000601:surgery; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008649:Mesonephroma / Q000188:drug therapy / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery
D005047:Etoposide; D002945:Cisplatin